Iodide

Iodide

SCHEMBL14740375

Nc1cc[n+](CCCCCC[n+]2ccc(N)c3ccccc32)c2ccccc12.[I-].[I-]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHKA P35790 2/20 0.55
PRKCA P17252 3/20 0.51
MEN1 O00255 1/20 0.51
GMNN O75496 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
GLA P06280 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
APEX1 P27695 1/20 0.51
MAPK1 P28482 1/20 0.51
RECQL P46063 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL14739218 1.00 CHKA (0.55) CHKAPRKCAMEN1GMNNALDH1A1
Iodide SCHEMBL2329322 1.00 CHKA (0.55) CHKAPRKCAMEN1GMNNALDH1A1
Iodide SCHEMBL14739174 1.00 CHKA (0.55) CHKAPRKCAMEN1GMNNALDH1A1
Iodide SCHEMBL14738732 1.00 CHKA (0.55) CHKAPRKCAMEN1GMNNALDH1A1
SCHEMBL17021411 0.98 CHKA (0.57) CHKA
SCHEMBL8907460 0.98 CHKA (0.57) CHKA
Iodide SCHEMBL14739303 0.98 CHKA (0.57) CHKA
SCHEMBL8908331 0.98 CHKA (0.57) CHKA
Bromide SCHEMBL18334835 0.96 CHKA (0.59) CHKA
SCHEMBL8912820 0.96 CHKA (0.58) CHKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity WASHINGTON UNIVERSITY (US) 2025-03-11 US disclosed
US-20230272449-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY WASHINGTON UNIVERSITY 2023-08-31 US disclosed
US-20200283820-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY WASHINGTON UNIVERSITY 2020-09-10 US disclosed
US-20190298841-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2019-10-03 US disclosed
US-10350299-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD. (GB) 2019-07-16 US disclosed
US-20170340745-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD. (GB) 2017-11-30 US disclosed
US-9669101-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD (GB) 2017-06-06 US disclosed
US-9550991-B2 Transcription factor decoys PROCARTA BIOSYSTEMS LTD. (GB) 2017-01-24 US disclosed
EP-2552455-B1 TRANSCRIPTION FACTOR DECOYS PROCARTA BIOSYSTEMS LTD (GB) 2016-12-28 EP disclosed
US-20150196652-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD (GB) 2015-07-16 US disclosed
US-9024005-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD (GB) 2015-05-05 US disclosed
US-20140274800-A1 TRANSCRIPTION FACTOR DECOYS FOR THE TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY BACTERIA INCLUDING CLOSTRIDIUM DIFFICILE PROCARTA BIOSYSTEMS LTD. (GB) 2014-09-18 US disclosed
US-20130252881-A1 Transcription Factor Decoys PROCARTA BIOSYSTEMS LTD. (GB) 2013-09-26 US disclosed
US-20130059775-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230272449-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY NADK, NAPRT, TIPARP CHKA 1743/4885PRKCA 2174/4885MEN1 3678/4885
US-10350299-B2 Nucleic acid complexes ZFR, SUB1, RELA CHKA 3864/4885PRKCA 4524/4885MEN1 4030/4885
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity NADK, NAPRT, TIPARP CHKA 1743/4885PRKCA 2174/4885MEN1 3678/4885
US-20170340745-A1 NUCLEIC ACID COMPLEXES ZFR, SUB1, RELA CHKA 3864/4885PRKCA 4524/4885MEN1 4030/4885
US-20200283820-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY NADK, NAPRT, TIPARP CHKA 1743/4885PRKCA 2174/4885MEN1 3678/4885
US-20190298841-A1 Nucleic Acid Complexes ZFR, SUB1, RELA CHKA 3864/4885PRKCA 4524/4885MEN1 4030/4885
US-20150196652-A1 NUCLEIC ACID COMPLEXES ZFR, SUB1, RELA CHKA 3864/4885PRKCA 4524/4885MEN1 4030/4885
US-20130059775-A1 Nucleic Acid Complexes ZFR, SUB1, RELA CHKA 3864/4885PRKCA 4524/4885MEN1 4030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.